Sunday, July 07, 2019 10:27:17 AM
Docnj,
-I recently posted the plight of a 55-year-old male I know who went into cardiac arrest. It wasn't long after he felt chest pain as he left for work. He was fortunate to have an ambulance stationed across the street in New Jersey where he lives. By the time he reached the hospital, he went into cardiac arrest. They opened up a major artery that was 100% occluded. He was back to work in two weeks. I emailed him "eye-opening" information on Vascepa to bring up with his Cardiologist and he did.
-The Cardiologist said, "that's a good drug, but I don't want to start you on any new meds, because we need to perform a second procedure". Apparently, the patient was experiencing shortness of breath on the follow-up visit and a second artery was 60% occluded. He had that done and he returned to work.
When I saw him afterwards, he didn't mention Vascepa, and I just knew he wasn't given a script for V. I went even further and emailed him the Preston Mason PhD presentation showing multi-factorial benefits of V and sent Twitter poster Terrapharma1's before and after photos of mice arteries treated with Icospapent Ethyl. I wrote frankly, that he shouldn't assume the Cardiologist would or will prescribe V, if he hasn't already, likely because of either the Doctor's ego because he didn't come up with the idea, or the Doctor is a robot who cares only about his routine procedures and isn't trained in the fine art of prevention. Finally, I stated: "if I was a patient in your shoes, I couldn't sleep at night for not having a script for V yesterday". I provided my Mom's cardiologist's contact info.
Conclusion: I've seen the patient at least three times since. Did he mention anything? "Crickets"
ILT
-I recently posted the plight of a 55-year-old male I know who went into cardiac arrest. It wasn't long after he felt chest pain as he left for work. He was fortunate to have an ambulance stationed across the street in New Jersey where he lives. By the time he reached the hospital, he went into cardiac arrest. They opened up a major artery that was 100% occluded. He was back to work in two weeks. I emailed him "eye-opening" information on Vascepa to bring up with his Cardiologist and he did.
-The Cardiologist said, "that's a good drug, but I don't want to start you on any new meds, because we need to perform a second procedure". Apparently, the patient was experiencing shortness of breath on the follow-up visit and a second artery was 60% occluded. He had that done and he returned to work.
When I saw him afterwards, he didn't mention Vascepa, and I just knew he wasn't given a script for V. I went even further and emailed him the Preston Mason PhD presentation showing multi-factorial benefits of V and sent Twitter poster Terrapharma1's before and after photos of mice arteries treated with Icospapent Ethyl. I wrote frankly, that he shouldn't assume the Cardiologist would or will prescribe V, if he hasn't already, likely because of either the Doctor's ego because he didn't come up with the idea, or the Doctor is a robot who cares only about his routine procedures and isn't trained in the fine art of prevention. Finally, I stated: "if I was a patient in your shoes, I couldn't sleep at night for not having a script for V yesterday". I provided my Mom's cardiologist's contact info.
Conclusion: I've seen the patient at least three times since. Did he mention anything? "Crickets"
ILT
Recent AMRN News
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
- New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients • GlobeNewswire Inc. • 11/09/2025 09:15:00 PM
- Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 • GlobeNewswire Inc. • 11/03/2025 01:30:00 PM
